News & Views | Published:

COMORBIDITIES

Optimization of CVD prevention in psoriatic arthritis

Nature Reviews Rheumatologyvolume 14pages323324 (2018) | Download Citation

Patients with psoriatic arthritis and other inflammatory joint diseases have a high risk of cardiovascular disease (CVD), but use relatively little preventive medication such as antihypertensive and lipid lowering agents. An unmet need exists for the optimization of CVD prevention in this high-risk patient population.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Agca, R. et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann. Rheum. Dis. 76, 17–28 (2017).

  2. 2.

    Eder, L. et al. Gaps in diagnosis and treatment of cardiovascular risk factors in patients with psoriatic disease: an international multicenter study. J. Rheumatol. 45, 378–384 (2018).

  3. 3.

    Wibetoe, G. et al. Cardiovascular disease risk profiles in inflammatory joint disease entities. Arthritis Res. Ther. 19, 153 (2017).

  4. 4.

    Gulati, A. M. et al. On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord-Trondelag health study. Ann. Rheum. Dis. 75, 819–824 (2016).

  5. 5.

    Eder, L. et al. Subclinical atherosclerosis in psoriatic arthritis: a case-control study. J. Rheumatol. 35, 877–882 (2008).

  6. 6.

    Piepoli, M. F. et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Eur. Heart J. 37, 2315–2381 (2016).

  7. 7.

    Semb, A. G. et al. Exploring cardiovascular disease risk evaluation in patients with inflammatory joint diseases. Int. J. Cardiol. 223, 331–336 (2016).

  8. 8.

    Eder, L., Chandran, V. & Gladman, D. D. The Framingham risk score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease. Ann. Rheum. Dis. 73, 1990–1996 (2014).

  9. 9.

    Kotseva, K. et al. EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur. J. Prev. Cardiol. 23, 636–648 (2016).

  10. 10.

    de Jong, M. J. et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet 390, 959–968 (2017).

Download references

Acknowledgements

The work of the authors is supported financially by grants from the South-Eastern Regional Health Authority of Norway (grant numbers 2013064 and 2016063).

Author information

Affiliations

  1. Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway

    • Anne Grete Semb
    •  & Silvia Rollefstad

Authors

  1. Search for Anne Grete Semb in:

  2. Search for Silvia Rollefstad in:

Competing interest

The authors declare no competing interests.

Corresponding author

Correspondence to Anne Grete Semb.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/s41584-018-0002-z

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing